CG Oncology, Inc. (CGON)
NASDAQ: CGON · IEX Real-Time Price · USD
35.22
-1.50 (-4.08%)
At close: Jul 19, 2024, 4:00 PM
35.23
+0.01 (0.03%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
CG Oncology Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for CG Oncology stock have an average target of 64, with a low estimate of 50 and a high estimate of 75. The average target predicts an increase of 81.71% from the current stock price of 35.22.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +84.55% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +112.95% | May 28, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $43 → $50 | Hold → Strong Buy | Upgrades | $43 → $50 | +41.96% | May 14, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $50 | Hold → Strong Buy | Upgrades | $50 | +41.96% | May 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +112.95% | May 10, 2024 |
Financial Forecast
Revenue This Year
1.69M
from 204.00K
Increased by 730.39%
Revenue Next Year
8.96M
from 1.69M
Increased by 428.63%
EPS This Year
-1.62
from -15.65
EPS Next Year
-1.93
from -1.62
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.7M | 34.1M | 130.1M | 238.4M | 435.8M |
| Avg | 1.7M | 9.0M | 97.3M | 170.3M | 406.8M |
| Low | 490,000 | n/a | 50.6M | 104.8M | 375.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1,716.2% | 1,914.5% | 1,352.3% | 144.9% | 155.9% |
| Avg | 730.4% | 428.6% | 986.7% | 75.0% | 138.9% |
| Low | 140.2% | - | 464.7% | 7.7% | 120.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.17 | -1.33 | -0.25 |
| Avg | -1.62 | -1.93 | -1.29 |
| Low | -2.07 | -2.36 | -2.38 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.